Puma Biotechnology Inc Stock News

Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Techne (TECH). But which of these two stocks is more attractive to val

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President an

Puma Biotech (PBYI) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to loss of $0.01 per share a year ago.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech (PBYI) and Techne (TECH). But which of these two stocks offers value investors a better bang for

The heavy selling pressure might have exhausted for Puma Biotech (PBYI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 2, 2023, following the release of its 3Q-2023 results.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Amgen (AMGN). But which of these two stocks is more attractive to valu

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Techne (TECH). But which of these two companies is the best option for those